Canaccord lowered the firm’s price target on Vertex Pharmaceuticals (VRTX) to $436 from $437 and keeps a Hold rating on the shares. The firm said they reported a slight top-line miss driven by lower-than-expected Trikafta sales, though it was mostly offset by the beat in Alyftrak sales.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VRTX:
- Vertex Pharmaceuticals Earnings Call Highlights New Growth Engines
- Closing Bell Movers: Pinterest jumps 15% on earnings beat; Palantir slips
- Moderna updates on Cystic Fibrosis collaboration with Vertex Pharmaceuticals
- Vertex Pharmaceuticals reports Q1 EPS $4.02, consensus $4.31
- Vertex Pharmaceuticals affirms FY26 revenue $12.95B-$13.1B, consensus $13.05B